ACT Initiates Treatment of Higher-Dosage Cohort in Clinical Trials for Dry Age-Related Macular Degeneration and Stargardt’s

  ACT Initiates Treatment of Higher-Dosage Cohort in Clinical Trials for Dry
  Age-Related Macular Degeneration and Stargardt’s Macular Dystrophy

 Patients in U.S. Clinical Trials Injected with 150,000 human embryonic stem
             cell-(hESC) derived Retinal Pigment Epithelial Cells

Business Wire

MARLBOROUGH, Mass. -- April 01, 2013

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of
regenerative medicine, today announced treatment of patients in the third
patient cohort, in each of its two U.S. clinical trials for forms of macular
degeneration. The patients were injected with 150,000 human embryonic stem
cell-(hESC) derived retinal pigment epithelial (RPE) cells, as compared with
the 100,000-cell dose used in the previous three patients of the second
cohort. The Stargardt’s Macular Dystrophy (SMD) patient was treated on
Wednesday, March 27, at Bascom Palmer Eye Institute at the University of Miami
Miller School of Medicine, with the patient with dry age-related macular
degeneration (dry AMD) having been treated the prior day, at another clinical
trial site. Both patients successfully underwent the outpatient
transplantation surgery, and are recovering uneventfully.

“We are very pleased to have commenced with treatment of the third patient
cohort in both of our U.S. clinical trials,” commented Gary Rabin, chairman
and CEO of ACT. “We are eagerly anticipating completing this cohort and moving
on to the fourth one. We are also looking forward to initiating treatment of
patients with better vision in cohort 2a, for which we are currently reviewing
and qualifying patients.”

Initiated in July 2011, the two Phase I trials are designed to determine the
safety and tolerability of hESC-derived RPE cells following sub-retinal
transplantation in patients with SMD and dry AMD at 12 months, the studies’
primary endpoint. Both trials will involve 16 patients, with cohorts of three
patients each in an ascending dosage format and four patients with better
vision, receiving 100,000 hESC-derived RPE cells. The company is concurrently
conducting a second trial for SMD in Europe.

“We have now treated 20 patients,” said Robert Lanza, M.D., chief scientific
officer. “We are encouraged by the steady progress of our U.S. clinical
trials, and are eagerly anticipating initiating treatment of the third patient
cohort in our European trial, as well.”

Further information about patient eligibility for ACT’s SMD study and the
concurrent studies in the U.S. and Europe (for dry age-related macular
degeneration and SMD, respectively) are available at www.clinicaltrials.gov,
with the following Identifiers: NCT01345006 (U.S. SMD), NCT01344993 (dry AMD),
and NCT01469832 (E.U. SMD).

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular
technology in the field of regenerative medicine. For more information, visit
http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating
results, future growth in research and development programs, potential
applications of our technology, opportunities for the company and any other
statements about the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including statements
containing the words “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates,” and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors that could
cause actual results or events to differ materially from those indicated by
such forward-looking statements, including: limited operating history, need
for future capital, risks inherent in the development and commercialization of
potential products, protection of our intellectual property, and economic
conditions generally. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed from time to
time in the company’s periodic reports, including the report on Form 10-K for
the year ended December 31, 2012. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. There can be no assurance that the Company’s
clinical trials will be successful.

Contact:

Investors:
CEOcast, Inc.
James Young, 212-732-4300
or
Press:
ACT Corporate Communications
Bill Douglass, 646-450-3615
or:
Russo Partners
Martina Schwarzkopf, Ph.D., 212-845-4292
 
Press spacebar to pause and continue. Press esc to stop.